Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at 3:30 p.m. ET.

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

Albireo to Report Second Quarter 2021 Financial Results on August 5

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). PFIC afflicts children with severe, progressive liver disease.

Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC).  Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi).

Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease

– First approval in the world of Bylvay for the treatment of PFIC –

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at 11:00 a.m. EDT.

Albireo to Present at the William Blair Biotech Focus Conference 2021

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandler's Virtual EASL Takeaway Day on Monday, June 28, at 10:00 a.m. EDT.

Albireo to Present at Piper Sandler's Virtual EASL Takeaway Day

Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data will be presented at the EASL International Liver Congress 2021.

Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –

Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress

– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –

Albireo to Showcase New Data at the EASL International Liver Congress™ 2021

– Data being presented show long-term benefits of Bylvay in children with PFIC –

New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, at 9:30 a.m. EDT and William Blair's 41st Annual Growth Stock Conference on Thursday, June 3, at 12:40 p.m. EDT. Members of the management team will also host meetings with investors June 1-3.

Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients aged six months or older. PFIC is a rare, life-threatening liver disease, and only about half of the children affected by the disease survive beyond the age of 10 years.

Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease

– Bylvay has the potential to become first approved drug to treat all forms of PFIC –

Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -

Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of -33.14% and -25.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ALBIREO PHARMA (ALBO) Reports Q1 Loss, Lags Revenue Estimates

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–

Albireo Reports Q1 Financial Results and Business Update

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

Albireo to Report First Quarter 2021 Financial Results on May 6

Albireo developed Odevixibat- a product as a pipeline - as a life saving therapy for multiple ultra rare pediatric liver disease indications.

Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –

News for Albireo Pharma Stock (ALBO)